Elevation Oncology Inc
NASDAQ:ELEV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Befesa SA
XETRA:BFSA
|
LU |
|
F
|
Fuerte Metals Corp
XTSX:FMT
|
CA |
|
NUeRNBERGER Beteiligungs AG
XETRA:NBG6
|
DE |
|
Next Biometrics Group ASA
OSE:NEXT
|
NO |
|
Raj Rayon Industries Ltd
NSE:RAJRILTD
|
IN |
|
Zalando SE
XETRA:ZAL
|
DE |
|
Fortuna Silver Mines Inc
TSX:FVI
|
CA |
|
M
|
MC Mining Ltd
ASX:MCM
|
AU |
|
G
|
Grand Baoxin Auto Group Ltd
HKEX:1293
|
CN |
|
T
|
Tiong Nam Logistics Holdings Bhd
KLSE:TNLOGIS
|
MY |
Elevation Oncology Inc
Research & Development
Elevation Oncology Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Elevation Oncology Inc
NASDAQ:ELEV
|
Research & Development
-$28.6m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Research & Development
-$523m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-31%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
Elevation Oncology Inc
Glance View
Elevation Oncology, Inc. operates as a precision oncology company. The company is headquartered in New York City, New York and currently employs 35 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company focuses on identifying oncogenic drivers with other driver alterations and in the conduct of clinical trials. Its lead drug development candidate, seribantumab, is an Anti-HER3 monoclonal antibody and potential targeted therapy for solid tumors driven by neuregulin-1 (NRG1) fusions, which are genomic alterations that are identified as oncogenic driver alterations. Its NRG1 is the primary activating ligand of HER3. The firm's clinical trial, CRESTONE, is a Phase II study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion.
See Also
What is Elevation Oncology Inc's Research & Development?
Research & Development
-28.6m
USD
Based on the financial report for Dec 31, 2024, Elevation Oncology Inc's Research & Development amounts to -28.6m USD.
What is Elevation Oncology Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-40%
Over the last year, the Research & Development growth was -12%. The average annual Research & Development growth rates for Elevation Oncology Inc have been -7% over the past three years , -40% over the past five years .
